Perseus Proteomics Inc.

Tokyo Stock Exchange 4882.T

Perseus Proteomics Inc. Net Income Margin for the year ending March 31, 2024: -1,100.04%

Perseus Proteomics Inc. Net Income Margin is -1,100.04% for the year ending March 31, 2024, a -31.67% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.
  • Perseus Proteomics Inc. Net Income Margin for the year ending March 31, 2023 was -835.45%, a -0.32% change year over year.
  • Perseus Proteomics Inc. Net Income Margin for the year ending March 31, 2022 was -832.76%, a -36.94% change year over year.
  • Perseus Proteomics Inc. Net Income Margin for the year ending March 31, 2021 was -608.14%, a 38.53% change year over year.
  • Perseus Proteomics Inc. Net Income Margin for the year ending March 31, 2020 was -989.41%.
Key data
Date Net Income Margin EBITDA Margin EBIT Margin EBITDA
Market news
Tokyo Stock Exchange: 4882.T

Perseus Proteomics Inc.

CEO Mr. Takuya Yokokawa
IPO Date June 22, 2021
Location Japan
Headquarters 30-1 Nihonbashi Hakozakicho
Employees 25
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.

StockViz Staff

January 16, 2025

Any question? Send us an email